Genmab CEO: Arbitration might be concluded in 2021

The legal strife between Genmab and its partner Janssen may be settled this year, according to Genmab CEO Jan van de Winkel, although he is not sure about the timing.

Photo: PR / Genmab

Genmab's dispute with its business partner over blockbuster drug Darzalex, the Johnson & Johnson-owned Janssen Biotech, may draw out.

"We can say very little. The timing is naturally uncertain, but you're summarizing it quite well. Yes, it may be decided in 2021, but it potentially could be in 2022," said Genmab CEO Jan van de Winkel on Wednesday at a teleconference.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs